Viz.ai
50+ FDA-cleared algorithms flag strokes within minutes of a CT scan
Overview
Viz LVO was the first AI software to win FDA De Novo clearance for detecting large-vessel-occlusion strokes on CT and auto-alerting the care team; Viz.ai now runs 50+ cleared algorithms across neuro, cardiac, vascular, pulmonary, trauma and oncology in nearly 2,000 US hospitals.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 1 Sep 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
- Viz.ai One care-coordination platform
- Priced per algorithm module
- Pilot programs on request
- Multi-site deployment
- Full module suite
- Dedicated clinical success support
Use cases
What you can produce with Viz.ai
- Sub-10-minute median CT-to-specialist-alert time for suspected LVO strokes
- Real-time mobile push notification to the neurovascular team with image thumbnails attached
- Automated ICH volume quantification report embedded in the clinical workflow
- Care coordination timeline dashboard for stroke network performance benchmarking
- FHIR/HL7-based EHR integration feeding AI findings directly into the patient chart
- Life sciences partner dashboard with de-identified, real-world patient-pathway insights
- Viz Assist workflow AI for clinical and administrative task automation within the hospital
ASEAN Perspective
Viz.ai in Southeast Asia
Viz.ai's clinical evidence base is drawn almost entirely from U.S. and European hospital networks, and no confirmed ASEAN or Asia-Pacific hospital deployments have been publicly announced as of mid-2026. Stroke burden in Southeast Asia is high — ASEAN countries account for a disproportionate share of global stroke mortality — making the platform's core use case directly relevant, but local regulatory clearances (HSA Singapore, BPOM Indonesia, Thai FDA, PMDA Japan) would need to be obtained before commercial deployment. Health systems in Singapore, Thailand, and Malaysia that wish to pilot AI stroke triage should also evaluate RapidAI and Aidoc, both of which have more documented APAC reference sites and may present lower localisation hurdles.
Viz.ai has the deployment record to back its claims: nearly 2,000 US hospitals, 50+ FDA-cleared algorithms, and outcomes data — a 44% cut in interfacility stroke transfer times, ~90% clinician click-through on alerts — that's been through peer review rather than living only in a press release. The 2018 De Novo clearance for Viz LVO set the regulatory template the rest of the AI-triage category has followed since.
The limitations are commercial, not clinical: enterprise-only pricing with no public rates or self-serve tier, a footprint that's almost entirely US-based, and an integration layer (FHIR/HL7/PACS into hospital systems) rather than a developer API. RapidAI edges it out on medium-vessel occlusions specifically; Aidoc covers a broader radiology triage scope. For APAC health systems, TGA/HSA/PMDA re-clearance and the lack of regional reference sites are real procurement hurdles.
What people say
A stroke patient's CT scan used to sit in a queue for a specialist to review — Viz.ai's whole business is built on collapsing that queue. Viz LVO, cleared by the FDA in 2018 as the first AI software ever to win De Novo clearance for stroke detection, reads the scan and pages the treating team directly, and the clinical data backs up the pitch: a 44% reduction in interfacility transfer times and roughly 90% of alerts getting clicked through by the receiving clinician.
The platform has scaled well past its original use case. More than 50 FDA-cleared algorithms now span neurovascular, cardiac, vascular, pulmonary, trauma and oncology conditions, deployed across nearly 2,000 US hospitals covering upward of 230 million lives. A life-sciences arm sells real-world clinical intelligence to 13 pharmaceutical partners, and the healthcare business reached profitability in 2025 on roughly $65 million in annual revenue.
What's missing is everything outside the US healthcare system. Pricing is enterprise-only and never published, there's no self-service tier, and the international footprint is thin — a nascent EU presence, no documented ASEAN deployments. The integration surface is built for hospital IT (FHIR, HL7, PACS), not third-party developers, so this isn't a platform smaller health-tech companies can build on top of. Competing products carve out specific edges: RapidAI in medium-vessel occlusion detection, Aidoc in broader radiology triage. For a large hospital system already running US-style imaging infrastructure, Viz.ai is close to the category standard; for anyone outside that footprint, it's aspirational rather than actionable today.
Summary of public user & expert reviews, compiled by RECATOOLS.
Notable facts
- Viz.ai's 2018 FDA De Novo clearance was the first ever granted for an AI clinical decision support tool in emergency imaging triage.
- The platform assists in the care of one patient approximately every 32 seconds across its hospital network.
- Co-founder Dr. Chris Mansi was inspired to start the company after a patient died from delayed stroke treatment despite successful surgery.
- Viz.ai reached unicorn status ($1.2B valuation) in April 2022 led by Tiger Global and Insight Partners.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Viz.ai's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Viz.ai unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Viz.ai directly →
Spotted something out of date? Suggest an update →
More in Healthcare
